BIOVIE INC. (BIVI) Corporate Subsidiaries
BIOVIE INC. (BIVI) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: BIVI
CIK: 1580149
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 06/30
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
EisnerAmper LLP
Auditor SinceSince 6/30/2019 12:00:00 AM
Lead Engagement PartnerLee Tomasso
Audit LocationIselin, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| DEF 14A | 2026-09-28 | 2026-09-28 | DEF 14A | 0001520138-26-000395 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-11 | CURRENT REPORT | 0001520138-26-000391 | View SEC Doc Filr Page |
| 424B5 | 2026-09-14 | — | 424B5 | 0001520138-26-000389 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-09-03 | — | SCHEDULE 13G Filing | 0001595888-26-000114 | View SEC Doc Filr Page |
| 4 | 2026-08-28 | 2026-08-28 | 4 Filing | 0001520138-26-000383 | View SEC Doc Filr Page |
| 4 | 2026-08-28 | 2026-08-28 | 4 Filing | 0001520138-26-000382 | View SEC Doc Filr Page |
| 4 | 2026-08-28 | 2026-08-28 | 4 Filing | 0001520138-26-000379 | View SEC Doc Filr Page |
| 4 | 2026-08-28 | 2026-08-27 | 4 Filing | 0001520138-26-000378 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-19 | — | SCHEDULE 13G Filing | 0001094891-26-000281 | View SEC Doc Filr Page |
| S-1/A | 2026-08-14 | — | FORM S-1 AMENDMENT NO.3 | 0001520138-26-000350 | View SEC Doc Filr Page |
| 10-K | 2026-08-13 | 2026-06-30 | FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 | 0001520138-26-000332 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-07 | — | SCHEDULE 13G/A Filing | 0000895421-26-000215 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-07 | — | SCHEDULE 13G Filing | 0000895421-26-000214 | View SEC Doc Filr Page |
| FWP | 2026-08-07 | — | FREE WRITING PROSPECTUS | 0001520138-26-000324 | View SEC Doc Filr Page |
| FWP | 2026-08-06 | — | FREE WRITING PROSPECTUS | 0001520138-26-000320 | View SEC Doc Filr Page |
| FWP | 2026-08-06 | — | FREE WRITING PROSPECTUS | 0001520138-26-000314 | View SEC Doc Filr Page |
| S-1/A | 2026-08-06 | — | FORM S-1 AMENDMENT NO. 2 | 0001520138-26-000313 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | CURRENT REPORT | 0001520138-26-000312 | View SEC Doc Filr Page |
| S-1/A | 2026-07-31 | — | FORM S-1 AMENDMENT NO. 1 | 0001520138-26-000299 | View SEC Doc Filr Page |
| S-1 | 2026-07-17 | — | FORM S-1 REGISTRATION STATEMENT | 0001520138-26-000276 | View SEC Doc Filr Page |
| EFFECT | 2026-06-29 | — | EFFECT Filing | 9999999995-26-002154 | View SEC Doc Filr Page |
| S-3 | 2026-06-18 | — | FORM S-3 REGISTRATION STATEMENT | 0001520138-26-000244 | View SEC Doc Filr Page |
| DRS | 2026-06-11 | — | DRS Filing | 0001520138-26-000230 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | FORM 10-Q FOR PERIOD ENDING MARCH 31, 2026 | 0001520138-26-000154 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2026-03-25 | — | SCHEDULE 13D Filing | 0001520138-26-000086 | View SEC Doc Filr Page |